| 2023-12-05 | -0.51 % |
|
| 2023-11-30 | +1.57 % |
|
| 2023-11-28 | -1.49 % |
|
| 2023-11-27 | -0.34 % |
|
| 2023-11-21 | +0.19 % |
|
| 2023-11-17 | -0.23 % |
- The article discusses the reasons behind the decline in Marsh & McLennan (MMC) stock. The main reason for the decline is the rise in healthcare costs, particularly in pharmacy benefit costs, which have been increasing steadily. Additionally, the article mentions that the cost increases are projected to continue in the future. Prescriptions drugs, especially those used for the treatment of diabetes and obesity, have been the fastest-growing component of health benefit cost. These drugs are expensive and their utilization has increased, leading to higher costs for health plans. Furthermore, the article mentions that new gene and cell therapies are also beginning to impact cost, as they are one-time, high-cost treatments. Despite the rising health plan costs, large employers have not shifted additional costs to employees through higher deductibles, copays, or out-of-pocket maximums. Instead, they are focusing on cost management strategies that do not shift additional costs to employees, such as steering patients to higher-quality care and providing more intensive care management.
|
| 2023-11-16 | +1.45 % |
|
| 2023-11-15 | -1.32 % |
|
| 2023-11-14 | -1.04 % |
|
| 2023-11-09 | +0.6 % |
|
| 2023-11-03 | +0.25 % |
|
| 2023-11-02 | +1.79 % |
|
| 2023-10-31 | +0.73 % |
|
| 2023-10-30 | +1.82 % |
|
| 2023-10-27 | -1.19 % |
|
| 2023-10-19 | +0.71 % |
|
| 2023-10-18 | -0.65 % |
|
| 2023-10-16 | +0.82 % |
|
| 2023-10-12 | -1.02 % |
|
| 2023-10-11 | +0.15 % |
|
| 2023-10-10 | -0.24 % |
|
| 2023-10-03 | -0.02 % |
|
| 2023-10-02 | -0.8 % |
|
| 2023-09-28 | +0.22 % |
|
| 2023-09-22 | +0.15 % |
|
| 2023-09-21 | -1.14 % |
|
| 2023-09-12 | +0.59 % |
|
| 2023-08-30 | -0.23 % |
|
| 2023-08-29 | +0.94 % |
|
| 2023-08-23 | +1.35 % |
|
| 2023-08-22 | +0.17 % |
|
| 2023-08-17 | -0.79 % |
|
| 2023-08-16 | +0.06 % |
|
| 2023-08-15 | -1.07 % |
|
| 2023-08-14 | +0.18 % |
- The article discusses Berkshire Hathaway's new investments in homebuilders DR Horton, Lennar, and NVR, which were disclosed in a regulatory filing. The investments were made during a down period for Berkshire's homebuilding and remodeling businesses, but the low inventory of existing homes for sale could benefit the homebuilders. The article also mentions that Berkshire was a net seller of stocks in the quarter, including its holdings in Marsh & McLennan. Therefore, it does not provide an explanation for the increase in Marsh & McLennan's stock.
- The article discusses Berkshire Hathaway's recent stock portfolio changes, including selling its stakes in Marsh & McLennan. The reason for Marsh & McLennan's stock going up is not mentioned in the article.
- The article discusses Berkshire Hathaway's new investments in homebuilders DR Horton, Lennar, and NVR, which were disclosed in a regulatory filing. The investments were made during a down period for Berkshire's homebuilding and remodeling businesses, but there is potential for new construction activity due to low inventory of existing homes for sale. The article does not specifically mention why the Marsh & McLennan stock went up.
|
| 2023-08-09 | +0.7 % |
|
| 2023-08-08 | -1.37 % |
|
| 2023-08-04 | -0.76 % |
|
| 2023-07-27 | -1.3 % |
|
| 2023-07-25 | +0.48 % |
|
| 2023-07-21 | +1.18 % |
|
| 2023-07-19 | -0.4 % |
|
| 2023-07-14 | +0.09 % |
|
| 2023-07-11 | +1.08 % |
|
| 2023-07-10 | +0.5 % |
|
| 2023-06-27 | +0.32 % |
|
| 2023-06-22 | +0.79 % |
|
| 2023-06-20 | -0.06 % |
|
| 2023-06-12 | +0.2 % |
|
| 2023-06-09 | +1.1 % |
|
| 2023-06-08 | +0.81 % |
|
